7a-hsdh enzyme mutants and uses thereof

CN122303173APending Publication Date: 2026-06-30ZHEJIANG SANMEN HYGECON PHARMA CO LTD +2
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
ZHEJIANG SANMEN HYGECON PHARMA CO LTD
Filing Date
2026-05-09
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Existing natural 7α-HSDH and its reported mutants have shortcomings in catalytic efficiency and thermal stability, resulting in low synthesis efficiency and high cost of UDCA, which limits the application of enzymatic synthesis of ursodeoxycholic acid.

Method used

A 7α-HSDH enzyme mutant was constructed, and its catalytic activity and thermal stability were improved through single mutation or combination mutation. Combined with a 7β-hydroxysteroid dehydrogenase and coenzyme regeneration system, the efficient conversion of chenodeoxycholic acid to ursodeoxycholic acid at room temperature was achieved.

Benefits of technology

It improves the relative and residual activity of the 7α-HSDH enzyme mutant, enhances thermal stability, reduces production costs, is suitable for large-scale industrial applications, and has mild reaction conditions with no byproducts.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122303173A_ABST
    Figure CN122303173A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of bioenzyme technology, specifically relating to a 7α-HSDH enzyme mutant and its applications. The 7α-HSDH enzyme mutant is obtained by single or combined mutations of the protein sequence of the wild-type 7α-HSDH enzyme as shown in SEQ ID NO:1; the single mutations include V50A, I56R, A126I, A129C, or A203P; the combined mutations include V50A / I56R, V50A / A203P, V50A / A126I, V50A / A129C, V50A / I56R / A126I, V50A / I56R / A203P, V50A / I56R / A129C, or V50A / I56R / A203P / A126I. The 7α-HSDH enzyme mutant of this invention exhibits significantly improved activity and stability, and can convert CDCA to UDCA, showing broad application prospects.
Need to check novelty before this filing date? Find Prior Art